Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
F. Hoffmann-La Roche Ltd / Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.
Lesen Sie auch
-
First Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in the initial treatment of extensive-stage small cell lung cancer (ES-SCLC)
Basel, 25 September 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase III IMpower133 study of Tecentriq (atezolizumab) plus carboplatin and etoposide
(chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). The analysis showed that Tecentriq and chemotherapy
helped people live significantly longer compared with chemotherapy alone (overall survival [OS]=12.3 versus 10.3 months; hazard ratio [HR]=0.70, 95% CI: 0.54-0.91; p=0.0069) in the
intention-to-treat (ITT) population. [1] The Tecentriq -based combination also significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with
chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77, 95% CI: 0.62-0.96; p=0.017). [1] Safety for the Tecentriq and
chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.
"The results with this Tecentriq combination in the initial treatment of extensive-stage small cell lung cancer represent the first clinically meaningful advance in the disease in over 20 years,"
said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development. "Our goal is to find treatment options for all types of lung cancer, and we are eager to work with
global health authorities to bring this Tecentriq regimen to people living with this particularly difficult-to-treat form of lung cancer as soon as possible."